摘要
1978年国立癌症研究所(NCI)就开始了异环磷酰(IF)的临床试用。早期单药应用的结果显示,该药对于复发的非何杰金淋巴瘤(NHL)(有效率29％)、各种肉瘤和其他实体瘤(有效率27％)均有效。随后又将IF与足叶乙甙(Vp—16)和大剂量阿糖胞苷(Ara—c)联合应用于淋巴瘤,或单与Vp—16联合应用于肉瘤和其它实体瘤,则疗效更加显著——NHL病人应用IF、Vp—16和Ara—c三药联合方案的有效率为69％,而仅用IF和Vp—16二药联合方案的有效率为41％。在肉瘤病人中,全部入组的45例病人(3例单药,42例IF和Vp—16)在单用化疗或在化疗前后辅以手术或放疗后均获无病生存,其中20例病人生存2—8年。18例目前仍无病生存。在这些病人中,有11例一直处于完全缓解。由于上述这些良好的结果,我们正进一步考虑将IF纳入NHL和肉瘤的一线治疗方案之中。
NCI trials with IF were initated in 1978. Initially the drug was used as a single agent, and showed activity in patients with recurrent non-Hodgkin's lymphoma(29 % response rate) and a variety of sarcomas and other solid tumors ( 27% response rate). Subsequently IF was combmed with Etoposide and high dose Ara-Cin lymphomas, and E-toposide alone in sarcomas and other solid tumors. Improved response rates were achieved with the drug combinations-69 % of non-Hodgkin's lymphoma patients treated with IF/ Etoposide/ Ara-C responded while the response rate for patients treated with IF/ Etoposide 41%. Among sarcoma patients, a total of 45 (3 treated with IF and 42 with IF/ Etoposide) achieved disease free status either with chemotherapy atone, or following surgery or radiation before after chemotherapy. Twenty of these patients remain alive for between 2 to 8 years, and 18 are currently deease-free, 11 of the 18 having remained in continuous complete remission. These results encouraged us to incorporate IF into primary protocols for both non-Hodkgin s lymphomas and sarcomas.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1992年第3期207-214,共8页
Chinese Journal of Cancer
